Format

Send to

Choose Destination
Future Med Chem. 2016 Jan;8(1):73-86. doi: 10.4155/fmc.15.166. Epub 2015 Dec 21.

Leaving the lysosome behind: novel developments in autophagy inhibition.

Author information

1
Center for Cancer & Cell Biology, Van Andel Research Institute, 333 Bostwick Avenue, Grand Rapids, MI 49503, USA.

Abstract

The search for a single silver bullet for the treatment of cancer has now been overshadowed by the identification of multiple therapeutic targets unique to each malignancy and even to each patient. In recent years, autophagy has emerged as one such therapeutic target. In response to both therapeutic and oncogenic stress, cancer cells upregulate and demonstrate an increased dependence upon this intracellular recycling process. Particularly in malignancies that currently lack targeted therapeutic options, autophagy inhibitors are the next hopeful prospects for the treatment of this disease. In this review, we discuss the rapid evolution of autophagy inhibitors from early lysosomotropic agents to next-generation lysosome-targeted drugs and beyond.

PMID:
26689099
PMCID:
PMC4886745
DOI:
10.4155/fmc.15.166
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center